Neurobiological Aspects of Depression: How Do They Affect Neurologic Disorders?

Depression in Neurologic Disorders: Diagnosis and Management

Volumn , Issue , 2012, Pages 10-27

  Hecimovic, Hrvoje ^a  

^a KBC Zagreb   (Croatia)

Author keywords

Amygdala; Cytokine; Dopamine; Epilepsy; Hippocampus; Limbic system; Magnetic resonance imaging; Major depressive disorder; Neurobiology; Neuroimmunomodulation; Neurological disorder; Norepinephrine; Positron emission tomography; Serotonin; Serotonin transporter

Indexed keywords

EID: 84886339511     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118348093.ch2     Document Type: Chapter

References (29)

1. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature, 455 (7215): 894-902, 2008.
2. Aan Het Rot M, Mathew SJ, Charney DS. Neurobiological mechanisms in major depressive disorder. CMAJ, 180(3): 305-313, 2009.
3. Sheline YI, Sanghavi M, Mintun MA, et al. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci, 19 (12): 5034-5043, 1999.
4. Drevets WC. Neuroimaging and neuropathological studies of depression: implications for the cognitive -emotional features of mood disorders. Curr Opin Neurobiol, 11 (2): 240-249, 2001.
5. Hado-Vieira R, Salvadore G, Luckenbaugh DA, et al. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry, 69 (6): 946-958, 2008.
6. Price JL. Prefrontal cortical networks related to visceral function and mood. Ann N Y Acad Sci, 877: 383-396, 1999.
7. Woolsey T, Hanaway J, Gado M. The Brain Atlas: A Visual Guide to the Human Central Nervous System, 2nd ed. Hoboken, NJ: John Wiley & Sons, Inc., 2003.
8. Duvernoy HM. The Human Hippocampus: Functional Anatomy, Vascularization and Serial Sections with MRI. Berlin, Germany: Springer -Verlag, 1998.
9. Delgado PL, Price LH, Miller HL, et al. Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug -free depressed patients. Arch Gen Psychiatry, 51 (11): 865-874, 1994.
10. Azmitia EC, Gannon PJ, Kheck NM, et al. Cellular localization of the 5 -HT1A receptor in primate brain neurons and glial cells. Neuropsychopharmacology, 14 (1): 35-46, 1996.
11. Gross C, Zhuang X, Stark K, et al. Serotonin1A receptor acts during development to establish normal anxiety -like behaviour in the adult. Nature, 416 (6879): 396-400, 2002.
12. Wong ML, Kling MA, Munson PJ, et al. Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin -releasing hormone. Proc Natl Acad Sci USA, 97 (1): 325-330, 2000.
13. Lambert G, Johansson M, Agren H, et al. Reduced brain norepinephrine and dopamine release in treatment -refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. Arch Gen Psychiatry, 57(8): 787-793, 2000.
14. Nestler EJ, Barrot M, DiLeone RJ, et al. Neurobiology of depression. Neuron, 34 (1): 13-25, 2002.
15. Coyle JT, Duman RS. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron, 38(2): 157-160, 2003.
16. Chen AC, Shirayama Y, Shin KH, et al. Expression of the cAMP response element binding protein (CREB) in hippocampus produces an antidepressant effect. Biol Psychiatry, 49 (9): 753-762, 2001.
17. Shirayama Y, Chen AC, Nakagawa S, et al. Brain -derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci, 22 (8): 3251-3261, 2002.
18. Chen B, Dowlatshahi D, MacQueen GM, et al. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry, 50 (4): 260-265, 2001.
19. Khairova RA, Hado-Vieira R, Du J, et al. A potential role for pro -infl ammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol, 12 (4): 561-578, 2009.
20. Hecimovic H, Gilliam F. Neurobiology of depression and new opportunities for treatment. In: Depression and Brain Dysfunction, eds. F Gilliam, AM Kanner, YI Sheline. New York: Taylor & Francis Group, 2005.
21. Mayberg HS, Lozano AM, Voon V, et al. Deep brain stimulation for treatment -resistant depression. Neuron, 45 (5): 651-660, 2005.
22. Gilliam F, Santos J, Vahle V, et al. Depression in epilepsy: ignoring clinical expression of neuronal network dysfunction? Epilepsia, 45, Suppl. 2: 28-33, 2004.
23. Sheline YI, Gado MH, Price JL. Amygdala core nuclei volumes are decreased in recurrent major depression. Neuroreport, 9 (9): 2023-2028, 1998.
24. Taylor WD, Steffens DC, MacFall JR, et al. White matter hyperintensity progression and late -life depression outcomes. Arch Gen Psychiatry, 60 (11): 1090-1096, 2003.
25. Meyer JH, Kruger S, Wilson AA, et al. Lower dopamine transporter binding potential in striatum during depression. Neuroreport, 12 (18): 4121-4125, 2001.
26. Drevets WC, Price JL, Simpson JR Jr., et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature, 386 (6627): 824-827, 1997.
27. Drevets WC, Frank E, Price JC, et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry, 46 (10): 1375-1387, 1999.
28. Hecimovic H, Goldstein JD, Sheline YI, et al. Mechanisms of depression in epilepsy from a clinical perspective. Epilepsy Behav, 4, Suppl. 3: S25 -S30, 2003.
29. Gilliam F, Hecimovic H, Sheline Y. Psychiatric comorbidity, health, and function in epilepsy. Epilepsy Behav, 4, Suppl. 4: S26 -S30, 2003.